Navigation Links
Olympus Biotech Names Oliver Burckhardt to President North America
Date:5/23/2011

HOPKINTON, Mass., May 23, 2011 /PRNewswire/ -- Olympus Biotech, an Olympus Corporation company, today announced the appointment of Oliver Burckhardt to the position of president of Olympus Biotech Corporation. In his new role, Mr. Burckhardt will lead the company's North American business and focus on expanding opportunities for the emerging regenerative medicine market. Mr. Burckhardt will also become a member of the Olympus Biotech Board of Directors.

"With nearly 20 years in the medical device industry, Oliver's extensive knowledge of the industry and global leadership experience will prove invaluable as we continue to grow Olympus Biotech," said Hitoshi Mizuno, CEO Olympus Biotech Corporation. "We look forward to benefiting from his immense expertise as we continue to lead the creation of this dynamic new field of medicine."

Before joining Olympus Biotech, Mr. Burckhardt most recently served as the international president and CEO of Scient'x Corp in Paris, France, where his strategic vision redefined the company's direction and resulted in double-digit growth. Mr. Burckhardt also served as president of Orthofix, Inc., where he was responsible for the global spine business unit. Prior to that, Mr. Burckhardt spent nine years with Aesculap, Inc. in various sales and marketing positions, including vice president of sales and marketing for the Aesculap Spine division in the United States.

"The Vision of Olympus Biotech to advance into regenerative medicine is the next logical step in the treatment of many medical pathologies and conditions. I am excited about the overall strategic thinking and the assets that are already in place, within Olympus, which represent a perfect starting point for this future oriented strategy," said Mr. Burckhardt. He added, "I look forward to joining the talented team at Olympus Biotech and leveraging my experience in the industry to generate further growth and success."

About Olympus Biotech Corporation

Olympus Biotech was established in December, 2010 as a wholly owned company of Olympus Corporation. The vision of Olympus Biotech is to improve the patient Quality of Life by developing and distributing Regenerative Medicine that stimulate the intrinsic healing capacity in the living body by the technological development of growth factors and biomaterials.

Media Contact:
Jessica Nelson
Kwittken & Company
(646) 747-7141
jnelson@kwitco.com


'/>"/>
SOURCE Olympus Biotech Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Gumz to Retire as President and CEO of Olympus Corporation of the Americas
2. Stryker Completes Sale of OP-1 for use in Orthopaedic Bone Applications to Olympus
3. Stryker Announces Definitive Agreement to Sell OP-1 for Use in Orthopaedic Bone Applications to Olympus
4. Olympus Launches 2011 National Innovation Awards Program
5. Olympus America Licenses Digital Pathology Patents to BioImagene, Inc.
6. Omnyx Licenses Olympus Digital Pathology Patents
7. Venture-Backed Biotech Generates Quicker Exits but Lower Multiples than Medical Device
8. Generex Biotechnology Corporation CEO Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
9. Generex Biotechnology Corporation CEO to Present Live, Online at RetailInvestorConferences.com on May 5th
10. Centocor Ortho Biotech Products, L.P. Voluntarily Withdraws NDA for Trabectedin
11. Immune Design Corp. Appoints Pharma and Biotech Executive Carlos V. Paya, MD, PhD as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... March 27, 2017 The National University ... and data analytics company, signed a Memorandum of ... healthcare delivery in the region. ... Health Research and Technology (BIGHEART) at NUS and ... topics related to healthcare IT and medical device ...
(Date:3/27/2017)... , March 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), ... successfully passed early toxicology and efficacy studies. The company ... target a specific protein, MAGE A, in an effort ... cancer. After 4 weeks of treatment ... show very little toxicity in a full toxicology report ...
(Date:3/27/2017)... 27, 2017  Sanderling Ventures, portfolio company, Torax ... division of Johnson & Johnson. Torax manufactures and markets ... of gastro-esophageal reflux disease (GERD). The LINK device ... and the procedure is currently available in the ... Medical was founded by Sanderling Ventures, Mayo Medical ...
Breaking Medicine Technology:
(Date:3/27/2017)... Eau Claire, WI (PRWEB) , ... March 27, ... ... currently accepting new patients for custom smile makeovers without requiring a ... needs including orthodontics, gum disease treatment, cosmetic dentistry and dental implants. Whether patients ...
(Date:3/27/2017)... and London UK (PRWEB) , ... March 27, ... ... speed, agility and ability to gain site attention and engagement over the household ... educational webinar will discuss how partnering with the right outsourcing ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... it will co-exhibit with technology partners LG Business Solutions at ATARC Federal ... Center in Washington D.C., will provide education and examination into the mobility tools ...
(Date:3/27/2017)... ... March 27, 2017 , ... M&S Technologies, the first ... for the Smart System® 20/20. CE Certification builds upon M&S's long-standing commitment to ... such as ANSI, ISO and proven test methods used in the field of ...
(Date:3/27/2017)... ... March 27, 2017 , ... Osteitis pubis may be commonplace ... injury, it occurs when the muscles around the pelvis become inflamed. Over time, ... lower torso, as well as accompanying tenderness and weakness. Without proper intervention, it ...
Breaking Medicine News(10 mins):